SCHEMBL6792949

SCHEMBL6792949

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1ccc(OCC(F)(F)C(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
HTT P42858 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
SMO Q99835 2/20 0.45
L3MBTL1 Q9Y468 4/20 0.44
MEN1 O00255 4/20 0.44
MAPT P10636 4/20 0.44
RAB9A P51151 3/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 3/20 0.44
NPC1 O15118 2/20 0.44
HPGD P15428 1/20 0.44
PAX8 Q06710 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
GAA P10253 2/20 0.42
POLB P06746 1/20 0.42
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793719 0.91 SMO (0.49) KMT2AHTTSMOMEN1MAPT
SCHEMBL7176725 0.90 KMT2A (0.48) KMT2AHTTSMN1; SMN2SMOL3MBTL1
SCHEMBL6795019 0.86 KDR (0.52) KMT2AHTTSMOL3MBTL1MEN1
SCHEMBL6796259 0.86 NPC1 (0.50) KMT2AHTTSMN1; SMN2SMOL3MBTL1
SCHEMBL6795010 0.85 RAB9A (0.55) KMT2AHTTSMN1; SMN2SMOMEN1
SCHEMBL6792042 0.85 NPC1 (0.52) KMT2AHTTSMN1; SMN2SMOMEN1
SCHEMBL6792821 0.84 GAA (0.48) KMT2AHTTSMN1; SMN2SMOL3MBTL1
SCHEMBL6793336 0.84 RAB9A (0.65) KMT2AHTTSMN1; SMN2SMOMEN1
SCHEMBL6792973 0.84 NPC1 (0.47) KMT2AHTTSMN1; SMN2SMOL3MBTL1
SCHEMBL6792178 0.84 MAPT (0.50) KMT2AHTTSMN1; SMN2SMOL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 KMT2A 2457/4885HTT 2566/4885SMN1; SMN2 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.